Tables | No. 32 | Special Reports | HIV Surveillance | Reports | Resource Library | HIV/AIDS

Table 1. Distribution of participants across project areas—Medical Monitoring Project, United States, 2021
Project area	No. sampled	No. participating	% participating^a	% of total
California (excluding Los Angeles County and San Francisco)	500	241	48.2	6.0
Chicago, IL	400	200	50.0	5.0
Delaware	400	195	48.8	4.9
Florida	800	244	30.5	6.1
Georgia	500	191	38.2	4.8
Houston, TX	400	171	42.8	4.3
Illinois (excluding Chicago)	200	91	45.5	2.3
Indiana	400	134	33.5	3.4
Los Angeles County, CA	400	181	45.3	4.5
Michigan	400	196	49.0	4.9
Mississippi	400	170	42.5	4.3
New Jersey	500	228	45.6	5.7
New York (excluding New York City)	200	89	44.5	2.2
New York City, NY	800	256	32.0	6.4
North Carolina	400	177	44.3	4.4
Oregon	400	185	46.3	4.6
Pennsylvania (excluding Philadelphia)	200	74	37.0	1.9
Philadelphia, PA	400	141	35.3	3.5
Puerto Rico	400	188	47.0	4.7
San Francisco, CA	400	157	39.3	3.9
Texas (excluding Houston)	400	180	45.0	4.5
Virginia	400	137	34.3	3.4
Washington	400	169	42.3	4.2
Total	9,700	3,995	41.2^b	100

Note. Percentages might not sum to 100 because of rounding.
^a Calculated by dividing number of participating respondents by the total number of persons sampled.
^b The national response rate, which is calculated by dividing the total number of eligible respondents by the sum of total eligible respondents and noneligible respondents, is 43.59%.

Table 2. Selected characteristics, including demographic characteristics, social determinants of health, and quality of life, among persons with diagnosed HIV infection—Medical Monitoring Project, United States, 2021
	No.^a	%^b	95% CI^c
Demographic characteristics
Age at time of interview (years)
18–24	59	1.7	1.2–2.3
25–29	202	5.7	4.5–6.8
30–34	336	9.9	8.7–11.1
35–39	305	8.3	7.3–9.4
40–44	365	9.5	8.3–10.6
45–49	391	10.3	8.9–11.7
50–54	531	12.9	11.5–14.4
55–59	679	16.6	14.8–18.3
60–64	568	13.0	12.0–14.0
≥65	559	12.1	10.9–13.3
Race/ethnicity
American Indian/Alaska Native	17	0.4	0.2–0.6
Asian	42	1.4	0.8–1.9
Black/African American	1,592	41.1	32.0–50.2
Hispanic/Latino^d	992	24.2	16.8–31.6
Native Hawaiian/other Pacific Islander	—	—	—
White	1,165	28.0	22.4–33.5
Multiple races	179	4.7	3.7–5.8
Gender
Cisgender male	2,918	74.8	71.6–78.0
Cisgender female	983	22.9	19.8–26.0
Transgender^e	91	2.3	1.9–2.7
Sexual orientation
Lesbian or gay	1,691	43.3	38.6–47.9
Heterosexual or straight	1,733	42.7	38.9–46.5
Bisexual	382	10.4	8.9–11.9
Other	126	3.6	3.0–4.1
Social determinants of health
Economic stability
Measures of housing instability
Unstable housing at any time, past 12 months^f
Yes	563	14.8	13.1–16.6
No	3,418	85.2	83.4–86.9
Homeless at any time, past 12 months^g
Yes	302	7.7	6.8–8.6
No	3,683	92.3	91.4–93.2
Unstable housing or homelessness, past 12 months^h
Yes	651	17.0	15.3–18.6
No	3,330	83.0	81.4–84.7
Hunger/food insecurityⁱ
Yes	607	15.7	14.2–17.3
No	3,369	84.3	82.7–85.8
Employment status^j
Employed	1,897	48.6	46.3–50.9
Unemployed or unable to work	1,544	39.0	36.0–42.0
Student	39	1.2	0.6–1.8
Retired	495	11.2	9.4–12.9
Combined yearly household income (US$)k
0–19,999	1,708	47.4	43.2–51.7
20,000–39,999	811	22.9	20.8–24.9
40,000–74,999	587	17.0	14.8–19.2
≥75,000	472	12.7	10.5–14.9
Household income with respect to poverty guidelines^l
<100% FPL	1,373	38.0	33.3–42.8
100–138% FPL	383	10.9	9.2–12.7
139–399% FPL	1,279	36.5	33.9–39.1
≥400% FPL	543	14.5	12.0–17.0
Received Supplemental Security Income (SSI), past 12 months
Yes	669	16.0	14.2–17.9
No	3,251	84.0	82.1–85.8
Received Social Security Disability Insurance (SSDI), past 12 months
Yes	778	19.1	17.4–20.7
No	3,142	80.9	79.3–82.6
Education
Educational attainment
Less than high school	583	14.9	12.4–17.4
High school diploma or GED	1,039	25.9	24.1–27.7
More than high school	2,354	59.2	56.0–62.5
Health-related factors
Confidence in completing health forms
Extremely	2,195	55.6	53.2–58.0
Quite a bit	822	20.3	18.2–22.5
Somewhat	502	12.8	11.6–14.1
A little bit	253	6.3	5.3–7.3
Not at all	197	4.9	4.1–5.8
Health insurance or coverage for care or medications (including Ryan White HIV/AIDS Program [RWHAP] assistance), past 12 months^m
Yes	3,912	98.8	98.3–99.4
No	32	1.2	0.6–1.7
Type of health insurance or coverage for care or medications, past 12 months^m
RWHAP assistance
Yes	1,897	47.1	44.2–50.0
No	1,926	52.9	50.0–55.8
Medicaid
Yes	1,705	43.4	39.9–46.9
No	2,164	56.6	53.1–60.1
Private health insuranceⁿ
Yes	1,609	42.3	39.8–44.8
No	2,227	57.7	55.2–60.2
Medicare
Yes	1,198	29.2	27.5–30.9
No	2,619	70.8	69.1–72.5
Other public insurance^o
Yes	—	—	—
No	—	—	—
Tricare/CHAMPUS or Veterans Administration
Yes	121	3.8	2.8–4.9
No	3,685	96.2	95.1–97.2
Insurance type unknown^p
Yes	60	1.7	1.2–2.1
No	3,750	98.3	97.9–98.8
Uninsured^q
Yes	314	9.5	6.4–12.6
No	3,630	90.5	87.4–93.6
Self-rated health
Poor	229	5.5	4.7–6.4
Fair	1,046	25.6	24.3–27.0
Good	1,332	33.9	32.3–35.5
Very good	872	22.1	20.4–23.8
Excellent	493	12.8	11.5–14.1
Any disability^r
Yes	1,674	40.6	38.4–42.9
No	2,303	59.4	57.1–61.6
Social and community context
Country or territory of birth
US state or territory	3,334	83.5	81.1–85.9
Outside the US and its territories	643	16.5	14.1–18.9
Incarcerated >24 hours, past 12 months
Yes	93	2.8	2.2–3.5
No	3,886	97.2	96.5–97.8
Total	3,995	100

Abbreviations: CI, confidence interval; GED, general educational development; FPL, federal poverty level; CHAMPUS, Civilian Health and Medical Program of the Uniformed Services; US$, US dollar; HHS, Department of Health and Human Services [footnotes only].
Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Hispanics or Latinos can be of any race. Persons are classified in only 1 race/ethnicity category.
^e Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose “transgender” in response to the question about self-identified gender.
^f Defined as moving in with others due to financial issues, moving 2 or more times, or being evicted at any time during the past 12 months.
^g Defined as living on the street, in a shelter, in a single-room–occupancy hotel, or in a car at any time during the past 12 months.
^h Defined as experiencing unstable housing (i.e., moving in with others due to financial issues, moving 2 or more times, or being evicted) or homelessness (living on the street, in a shelter, in a single-room–occupancy hotel, or in a car) at any time during the past 12 months.
ⁱ “Hunger/food insecurity” defined as going without food due to lack of money during the past 12 months.
^j Employed included employed for wages, self-employed, or homemaker.
^k Income from all sources, before taxes, in the last calendar year.
^l Poverty guidelines as defined by HHS; the 2020 guidelines were used for persons interviewed in 2021 and the 2021 guidelines were used for persons interviewed in 2022. More information regarding HHS poverty guidelines can be found at https://aspe.hhs.gov/frequently-asked-questions-related-poverty-guidelines-and-poverty.
^m Persons could select more than 1 response for health insurance or coverage for care or medications (including antiretroviral medications).
ⁿ Defined as receiving health insurance through a person’s employer or a family member’s employer or purchased through the Health Insurance Marketplace or directly from a health insurance company.
^o Other public insurance included city, county, state, or other publicly funded insurance, not including Medicaid.
^p Unknown insurance type means that the person had health insurance or coverage for care or medications (including antiretroviral medications), but the type of insurance or coverage could not be determined.
^q Includes those who did not report having any insurance, or received RWHAP assistance only, without coverage through any other insurance categories.
^r Includes physical, mental, and emotional disabilities.

Table 3. Time since HIV diagnosis, stage of disease, CD4 counts, and viral suppression during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, United States, 2021
	No.^a	%^b	95% CI^c
Time since HIV diagnosis (years)^d
<5	482	13.2	11.6–14.8
5–9	662	17.6	16.2–19.0
≥10	2,846	69.2	67.4–71.0
HIV infection stage 3 (AIDS)^e
Yes	2,188	53.1	51.1–55.0
No	1,806	46.9	45.0–48.9
Geometric mean CD4 count (cells/µL)
0–199	203	7.0	5.9–8.2
200–349	291	9.6	8.1–11.0
350–499	496	16.8	15.2–18.4
≥500	2,004	66.5	63.9–69.2
Lowest CD4 count (cells/µL), past 12 months
0–49	70	2.5	1.3–3.6
50–199	178	6.2	5.2–7.1
200–349	357	11.6	10.2–13.1
350–499	562	18.9	17.1–20.6
≥500	1,829	60.9	58.0–63.7
Viral suppression
Most recent viral load documented undetectable or <200 copies/mL	2,870	66.2	63.7–68.7
Most recent viral load documented detectable, ≥200 copies/mL, or missing/unknown	1,125	33.8	31.3–36.3
Sustained viral suppression
All viral load measurements documented undetectable or <200 copies/mL	2,705	62.4	60.2–64.6
Any viral load ≥200 copies/mL or missing/unknown	1,290	37.6	35.4–39.8
Total	3,995	100

Abbreviations: CD4, CD4 T-lymphocyte count (cells/µL); CI, confidence interval; CDC, Centers for Disease Control and Prevention [footnotes only].
Source of disease stage information: CDC. Revised surveillance case definition for HIV infection–United States, 2014. MMWR 2014;63(RR-03):1–10. https://www.cdc.gov/mmwr/indrr_2014.html. Accessed July 21, 2023.
Note. CD4 counts and viral load measurements are from medical record abstraction. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Determined based on date of HIV diagnosis from the National HIV Surveillance System.
^e HIV infection, stage 3 (AIDS): documentation of an AIDS-defining condition or either a CD4 count of <200 cells/µL or a CD4 percentage of total lymphocytes of <14. Documentation of an AIDS-defining condition supersedes a CD4 count or percentage that would not, by itself, be the basis for a stage 3 (AIDS) classification.

Table 4. Receipt of HIV care, ART prescription, PCP prophylaxis, and influenza vaccination among persons with diagnosed HIV—Medical Monitoring Project, United States, 2021
	No.^a	%^b	95% CI^c
Ever received outpatient HIV care^d
Yes	—	—	—
No	—	—	—
Received outpatient HIV care, past 12 months^d
Yes	3,887	94.9	93.3–96.5
No	106	5.1	3.5–6.7
Received outpatient HIV care, past 24 months^d
Yes	3,946	97.9	97.1–98.7
No	38	2.1	1.3–2.9
Retained in care, past 12 months^e
Yes	2,964	71.2	68.1–74.3
No	880	28.8	25.7–31.9
Retained in care, past 24 months^e
Yes	2,095	51.1	47.3–54.8
No	1,742	48.9	45.2–52.7
Missed ≥1 HIV care visits, past 12 months
Yes	756	19.4	17.7–21.0
No	3,198	80.6	79.0–82.3
Prescribed ART, past 12 months^f
Yes	3,361	80.4	78.1–82.7
No	634	19.6	17.3–21.9
Prescribed PCP prophylaxis, past 12 months^g
Yes	66	28.5	21.4–35.6
No	157	71.5	64.4–78.6
Received influenza vaccination, past 12 months
Yes	2,833	69.5	67.1–71.9
No	1,115	30.5	28.1–32.9
Total	3,995	100

Abbreviations: CI, confidence interval; ART, antiretroviral therapy; PCP, Pneumocystis pneumonia; MAC, Mycobacterium avium complex [footnotes only]; CD4, CD4 T-lymphocyte count (cells/µL) [footnotes only].
Note. CD4 counts, viral load measurements, and prophylaxes are from medical record abstraction. Influenza vaccination was obtained through interview. Measurement period is the 12 months before interview unless otherwise noted.
Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Outpatient HIV care was defined as any documentation of the following: encounter with an HIV care provider, viral load test result, CD4 test result, HIV resistance test or tropism assay, ART prescription, PCP prophylaxis, or MAC prophylaxis.
^e Two elements of outpatient HIV care at least 90 days apart in each 12-month period.
^f ART prescription documented in medical record; persons with no medical record abstraction were considered to have no documentation of ART prescription.
^g Among persons with CD4 cell counts <200 cells/mm³.

Table 5. Sexually transmitted infection testing during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, United States, 2021
	Total population			Sexually active^a persons only
	No.^b	col %^c	95% CI^d	No.^b	col %^c	95% CI^d
Gonorrhea^e
Yes, received test	1,570	41.1	37.3–44.9	1,020	48.6	45.0–52.2
No test documented	2,121	58.9	55.1–62.7	973	51.4	47.8–55.0
Chlamydia^f
Yes, received test	1,581	41.3	37.3–45.3	1,025	48.8	44.7–52.8
No test documented	2,110	58.7	54.7–62.7	968	51.2	47.2–55.3
Syphilis^g
Yes, received test	2,162	56.6	54.2–59.0	1,279	61.6	58.6–64.7
No test documented	1,529	43.4	41.0–45.8	714	38.4	35.3–41.4
Gonorrhea, chlamydia, and syphilis
Yes, received all 3 tests	1,354	35.5	32.4–38.7	886	42.4	38.8–46.0
Fewer than 3 tests documented	2,337	64.5	61.3–67.6	1,107	57.6	54.0–61.2
Total	3,995	100		2,161	100

Abbreviations: CI, confidence interval; DFA, direct fluorescent antibody [footnotes only]; EIA, enzyme immunoassay [footnotes only]; ELISA, enzyme-linked immunoassay [footnotes only]; FTA-ABS, fluorescent treponemal antibody absorbed [footnotes only]; MHA-TP, microhemagglutination assay for antibody to Treponema pallidum [footnotes only]; NAAT, nucleic acid amplification test [footnotes only]; RPR, rapid plasma reagin [footnotes only]; TP-PA, T. pallidum particle agglutination [footnotes only]; TPHA, T. pallidum hemagglutination assay [footnotes only]; VDRL, Venereal Disease Research Laboratory [footnotes only].
Note. Information on laboratory testing for sexually transmitted infections was based on medical record abstraction.
Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
^a Sexual activity was reported in the interview component of the Medical Monitoring Project and was defined as anal or vaginal intercourse during the 12 months prior to interview.
^b Numbers are unweighted.
^c Percentages are weighted percentages.
^d CIs incorporate weighted percentages.
^e Testing for Neisseria gonorrhoeae was defined as documentation of a result from culture, DFA, gram stain, EIA or ELISA, NAAT, or nucleic acid probe performed on a specimen from any anatomical site for screening or diagnostic purposes.
^f Chlamydia trachomatis testing was defined as a result from DFA, EIA or ELISA, NAAT, or nucleic acid probe performed on a specimen from any anatomical site for screening or diagnostic purposes.
^g Syphilis testing was defined as a result from nontreponemal syphilis tests (RPR or VDRL), treponemal syphilis tests (TPHA, TP-PA, MHA-TP, or FTA-ABS tests), or dark-field microscopy performed for screening or diagnostic purposes.

Table 6. Emergency department visits and hospital admissions during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, United States, 2021
	No.^a	%^b	95% CI^c
Number of visits to emergency department
0	2,501	63.5	61.4–65.5
1	693	17.1	16.0–18.2
2–4	610	15.1	13.6–16.6
≥5	169	4.4	3.2–5.6
Number of hospital admissions
0	3,283	83.3	81.9–84.8
1	377	9.3	8.3–10.2
2–4	254	6.1	5.1–7.1
≥5	53	1.3	0.8–1.9
Total	3,995	100

Abbreviation: CI, confidence interval.
Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.

Table 7. Antiretroviral therapy (ART) use and reasons for not taking ART among persons with diagnosed HIV—Medical Monitoring Project, United States, 2021
	No.^a	%^b	95% CI^c
Ever taken ART
Yes	3,926	98.4	97.9–99.0
No	40	1.6	1.0–2.1
Currently taking ART
Yes	3,837	94.9	93.8–95.9
No	127	5.1	4.1–6.2
Reasons for never taking ART^d
Health care provider said person should not start taking ART
Yes	10	37.5*	15.9–59.0
No	11	62.5*	41.0–84.1
Person thinks ART would make them feel sick or harm them
Yes	7	36.4*	15.6–57.3
No	20	63.6*	42.7–84.4
Person did not believe they needed ART
Yes	—	—	—
No	—	—	—
Health care provider never discussed taking ART with person
Yes	—	—	—
No	—	—	—
Money or insurance problems
Yes	—	—	—
No	—	—	—
Reasons for not currently taking ART, among those persons with a history of ART use^d
Money or insurance problems
Yes	33	41.1	29.2–53.0
No	53	58.9	47.0–70.8
Person thinks ART would make them feel sick or harm them
Yes	18	25.5	12.6–38.4
No	69	74.5	61.6–87.4
Person did not believe they needed ART
Yes	16	21.4	10.4–32.3
No	68	78.6	67.7–89.6
Health care provider never discussed restarting ART with person
Yes	—	—	—
No	—	—	—
Health care provider said person should not take ART
Yes	—	—	—
No	—	—	—
Total	3,995	100

Abbreviation: CI, confidence interval.
Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30.
Estimates with an absolute CI width >30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (*) and should be interpreted with caution.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Persons could select more than 1 response for reasons not taking ART.

Table 8. Antiretroviral therapy (ART) adherence and reasons for missing ART doses among persons with diagnosed HIV taking ART—Medical Monitoring Project, United States, 2021
	No.^a	%^b	95% CI^c
ART adherence in the past 30 days
How many days did you miss at least 1 dose of any of your HIV medicines?
0	2,415	63.1	61.6–64.6
1–2	935	24.1	22.6–25.5
3–5	311	8.1	7.0–9.2
6–10	106	3.2	2.5–3.8
≥11	55	1.6	1.2–2.0
How well did you do at taking your HIV medicines in the way you were supposed to?
Very poor	56	1.7	1.2–2.3
Poor	33	0.8	0.6–1.1
Fair	164	4.5	3.7–5.3
Good	378	10.0	8.0–12.0
Very good	937	25.0	23.3–26.8
Excellent	2,264	58.0	55.9–60.0
How often did you take your HIV medicines in the way you were supposed to?
Never	23	0.6	0.3–1.0
Rarely	34	1.1	0.7–1.6
Sometimes	73	2.2	1.6–2.8
Usually	144	3.7	3.0–4.3
Almost always	814	21.1	19.9–22.4
Always	2,742	71.3	69.8–72.8
How often were you troubled by ART side effects?
Never	3,074	80.0	78.4–81.5
Rarely	433	11.8	10.8–12.9
About half of the time	154	4.3	3.6–5.0
Most of the time	77	2.0	1.3–2.6
Always	76	1.9	1.4–2.4
Reasons for last missed ART dose among persons who ever missed a dose^d
Forgot to take HIV medicines
Yes	927	65.4	62.7–68.1
No	479	34.6	31.9–37.3
Change in daily routine or were out of town
Yes	576	41.6	38.4–44.8
No	830	58.4	55.2–61.6
Fell asleep early or overslept
Yes	557	40.3	36.0–44.7
No	849	59.7	55.3–64.0
Felt depressed or overwhelmed
Yes	241	16.9	14.5–19.3
No	1,164	83.1	80.7–85.5
Had a problem getting a prescription or a refill for HIV medicines
Yes	223	16.4	14.3–18.4
No	1,183	83.6	81.6–85.7
Did not feel like taking HIV medicines
Yes	165	12.1	9.8–14.3
No	1,238	87.9	85.7–90.2
Was drinking or using drugs
Yes	153	10.7	8.6–12.9
No	1,252	89.3	87.1–91.4
Had side effects from your HIV medicines
Yes	86	6.7	5.2–8.2
No	1,318	93.3	91.8–94.8
In the hospital or too sick to take HIV medicines
Yes	100	6.5	4.3–8.7
No	1,306	93.5	91.3–95.7
Had a problem paying for HIV medicines
Yes	50	3.6	2.6–4.7
No	1,357	96.4	95.3–97.4
Total	3,837	100

Abbreviation: CI, confidence interval.
Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Persons could report more than 1 reason for missed last dose.

Part 1/2. Table 9a. Antiretroviral therapy (ART) prescription, ART dose adherence, sustained viral suppression, and geometric mean CD4 count among persons with diagnosed HIV, by selected demographic characteristics—Medical Monitoring Project, United States, 2021
	Prescription of ART^a			ART dose adherence^b
	No.^e	Row %^f	95% CI^g	No.^e	Row %^f	95% CI^g
Gender
Cisgender male	2,454	80.3	77.5–83.0	1,773	63.1	61.4–64.8
Cisgender female	831	80.9	77.4–84.3	595	64.1	60.6–67.6
Transgender^h	74	79.3	71.2–87.5	46	52.0	38.5–65.4
Sexual orientation
Lesbian or gay	1,442	81.2	78.7–83.8	1,035	62.7	60.2–65.3
Heterosexual or straight	1,451	80.2	77.3–83.1	1,085	66.4	63.7–69.2
Bisexual	318	79.1	74.2–84.0	205	56.2	50.7–61.8
Other	102	76.1	64.5–87.7	61	48.2	40.1–56.2
Race/ethnicity
American Indian/Alaska Native	—	—	—	—	—	—
Asian	36	85.7	72.8–98.6	31	79.1*	61.1–97.1
Black/African American	1,313	78.5	74.8–82.2	903	59.6	56.4–62.8
Hispanic/Latinoⁱ	842	80.8	77.5–84.2	589	62.3	58.7–66.0
Native Hawaiian/other Pacific Islander	—	—	—	—	—	—
White	996	82.6	79.5–85.8	776	69.0	66.4–71.5
Multiple races	150	76.7	66.3–87.2	102	57.4	49.3–65.5
Age at time of interview (years)
18–29	207	72.8	66.2–79.4	108	44.3	38.0–50.7
30–39	529	77.4	73.2–81.7	317	53.5	49.1–57.8
40–49	630	80.0	76.7–83.3	428	60.5	56.5–64.6
>50	1,995	82.5	80.2–84.8	1,562	69.3	67.3–71.4
Total	3,361	80.4	78.1–82.7	2,415	63.1	61.6–64.6

Part 2/2. Table 9a. Antiretroviral therapy (ART) prescription, ART dose adherence, sustained viral suppression, and geometric mean CD4 count among persons with diagnosed HIV, by selected demographic characteristics—Medical Monitoring Project, United States, 2021
	Sustained viral suppression^c			Geometric mean CD4 count ≥200^d
	No.^e	Row %^f	95% CI^g	No.^e	Row %^f	95% CI^g
Gender
Cisgender male	1,976	62.3	59.9–64.7	2,035	93.0	91.7–94.3
Cisgender female	671	63.3	58.6–67.9	692	93.1	91.4–94.9
Transgender^h	57	56.8	42.9–70.7	63	90.9	83.1–98.6
Sexual orientation
Lesbian or gay	1,175	63.3	60.1–66.4	1,202	94.5	93.0–96.0
Heterosexual or straight	1,164	62.1	58.3–65.9	1,203	91.4	90.0–92.8
Bisexual	246	59.9	54.6–65.1	264	93.7	90.5–96.9
Other	86	65.4	54.2–76.6	84	92.8	85.8–99.7
Race/ethnicity
American Indian/Alaska Native	—	—	—	—	—	—
Asian	32	67.1*	48.3–85.9	29	94.0	86.7–100.0
Black/African American	1,006	59.1	55.3–62.9	1,102	92.3	90.8–93.8
Hispanic/Latinoⁱ	704	65.5	60.5–70.6	703	92.7	90.2–95.2
Native Hawaiian/other Pacific Islander	—	—	—	—	—	—
White	825	64.7	60.2–69.2	820	95.0	93.7–96.3
Multiple races	121	58.8	46.5–71.1	119	89.1	82.6–95.5
Age at time of interview (years)
18–29	143	49.6	43.3–56.0	179	94.6	91.7–97.6
30–39	402	56.5	52.0–60.9	441	93.7	91.1–96.3
40–49	493	62.6	58.0–67.2	529	93.0	90.8–95.2
>50	1,667	66.0	63.1–68.8	1,642	92.5	91.2–93.8
Total	2,705	62.4	60.2–64.6	2,791	93.0	91.8–94.1

Abbreviations: ART, antiretroviral therapy; CD4, CD4 T-lymphocyte count (cells/µL); CI, confidence interval.
Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30.
Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (*) and should be interpreted with caution.
^a Prescription of ART was based on documentation in the medical record in the 12 months before interview.
^b During the 30 days before interview, 100% adherence to ART doses.
^c Defined as having all HIV viral loads being undetectable or <200 copies/mL, as documented in the medical record in the past 12 months before interview.
^d Geometric mean CD4 count was abstracted from medical records and based on the 12 months before interview.
^e Numbers are unweighted.
^f Percentages are weighted percentages.
^g CIs incorporate weighted percentages.
^h Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose “transgender” in response to the question about self-identified gender.
ⁱ Hispanics or Latinos can be of any race. Persons are classified in only 1 race/ethnicity category.

Part 1/2. Table 9b. Antiretroviral therapy (ART) prescription, ART dose adherence, sustained viral suppression, and geometric mean CD4 count among persons with diagnosed HIV, by cycle year—Medical Monitoring Project, United States, 2015–2021
	Prescription of ART^a			ART dose adherence^b
	No.^e	Row %^f	95% CI^g	No.^e	Row %^f	95% CI^g
Cycle year
2015	3,244	85.3	83.6–87.0	2,018	59.5	57.1–61.9
2016	3,575	84.0	80.7–87.3	2,239	58.5	56.3–60.7
2017	3,741	84.2	82.3–86.1	2,396	60.8	59.1–62.5
2018	3,490	81.2	79.3–83.2	2,279	59.3	57.0–61.6
2019	3,542	82.6	80.9–84.3	2,385	61.1	58.5–63.8
2020	3,104	78.7	76.2–81.3	2,247	62.1	60.0–64.1
2021	3,361	80.4	78.1–82.7	2,415	63.1	61.6–64.6
Total	24,057	82.3	81.4–83.1	15,979	60.7	59.9–61.5

Part 2/2. Table 9b. Antiretroviral therapy (ART) prescription, ART dose adherence, sustained viral suppression, and geometric mean CD4 count among persons with diagnosed HIV, by cycle year—Medical Monitoring Project, United States, 2015–2021
	Sustained viral suppression^c			Geometric mean CD4 count >200^d
	No.e	Row %^f	95% CI^g	No.^e	Row %^f	95% CI^g
Cycle year
2015	2,415	62.5	59.6–65.4	2,891	91.0	89.0–93.0
2016	2,812	65.5	62.9–68.1	3,165	91.8	90.7–92.9
2017	2,862	63.2	59.9–66.5	3,264	92.2	91.1–93.3
2018	2,702	62.2	59.5–64.9	3,032	93.0	91.9–94.1
2019	2,707	61.0	56.4–65.5	3,005	91.7	90.8–92.7
2020	2,403	58.5	54.3–62.7	2,534	92.8	91.7–93.9
2021	2,705	62.4	60.2–64.6	2,791	93.0	91.8–94.1
Total	18,606	62.1	60.9–63.4	20,682	92.2	91.7–92.7

Abbreviations: ART, antiretroviral therapy; CD4, CD4 T-lymphocyte count (cells/µL); CI, confidence interval.
Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
^a Prescription of ART was based on documentation in the medical record in the 12 months before interview.
^b During the 30 days before interview, 100% adherence to ART doses.
^c Defined as having all HIV viral loads being undetectable or <200 copies/mL, as documented in the medical record in the past 12 months before interview.
^d Geometric mean CD4 count was abstracted from medical records and based on the 12 months before interview.
^e Numbers are unweighted.
^f Percentages are weighted percentages.
^g CIs incorporate weighted percentages.

Table 10. Symptoms of depression and generalized anxiety disorder during the 2 weeks before interview among persons with diagnosed HIV—Medical Monitoring Project, United States, 2021
	No.^a	%^b	95% CI^c
Symptoms of depression, based on DSM-IV criteria^d
No depression	3,315	84.7	83.2–86.1
Major depression	343	8.6	7.5–9.8
Other depression	270	6.7	5.8–7.6
Symptoms of moderate or severe depression (PHQ-8 score ≥10)
Yes	500	12.5	11.0–13.9
No	3,428	87.5	86.1–89.0
Symptoms of generalized anxiety disorder^e
No anxiety	3,133	79.4	77.5–81.3
Mild anxiety	208	5.3	4.3–6.3
Moderate anxiety	294	7.5	6.6–8.4
Severe anxiety	303	7.9	6.8–8.9
Total	3,995	100

Abbreviations: CI, confidence interval; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition; GAD-7, Generalized Anxiety Disorder 7-item Scale [footnotes only]; PHQ-8, Patient Health Questionnaire.
Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Responses to the items on PHQ-8 were used to define “major depression” and “other depression” according to criteria from the DSM-IV. To meet the criteria for major depression, a participant must have experienced 5 or more symptoms at least “more than half the days,” and one of the symptoms must be anhedonia or feelings of hopelessness. For other depression, a participant must have experienced 2 to 4 symptoms at least “more than half the days,” and one of the symptoms must be anhedonia or feelings of hopelessness.
^e Responses to the GAD–7 were used to define “mild anxiety,” “moderate anxiety,” and “severe anxiety” according to criteria from the DSM-IV. “Severe anxiety” was defined as having a score of ≥15; “moderate anxiety” was defined as having a score of 10–14; and “mild anxiety” was defined as having a score of 5–9.

Table 11. Tobacco and electronic cigarette or other vaping device use among persons with diagnosed HIV—Medical Monitoring Project, United States, 2021
	No.^a	%^b	95% CI^c
Smoked ≥100 cigarettes (lifetime)
Yes	2,072	51.7	49.4–54.0
No	1,878	48.3	46.0–50.6
Cigarette smoking status
Current smoker	1,128	29.2	26.6–31.8
Former smoker	941	22.5	20.7–24.3
Never smoked	1,878	48.3	46.0–50.6
Frequency of current cigarette smoking
Daily	911	23.4	21.1–25.7
Weekly	98	2.8	2.0–3.5
Monthly	36	0.9	0.7–1.2
Less than monthly	83	2.1	1.7–2.5
Never	2,819	70.8	68.2–73.4
Smoked ≥50 cigars, cigarillos, or little filtered cigars (lifetime)
Yes	600	15.6	14.0–17.2
No	3,348	84.4	82.8–86.0
Cigars, cigarillos, or little filtered cigars smoking status
Current smoker	283	7.7	6.7–8.8
Former smoker	317	7.9	7.0–8.9
Never smoked	3,348	84.4	82.8–86.0
Frequency of current cigars, cigarillos, or little filtered cigars smoking
Daily	104	2.6	1.8–3.5
Some days	76	2.1	1.4–2.7
Rarely	103	3.0	2.4–3.6
Never	3,665	92.3	91.2–93.3
Electronic cigarette or other vaping device smoking status^d
Used in the past 30 days	584	15.6	13.7–17.4
Used, but not in the past 30 days	543	14.4	12.3–16.5
Never used	2,820	70.1	66.8–73.4
Total	3,995	100

Abbreviation: CI, confidence interval.
Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Includes nicotine, tobacco, marijuana, flavoring, or any other substances.

Table 12. Alcohol use during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, United States, 2021
	No.^a	%^b	95% CI^c
Any alcohol use^d
Yes	2,532	64.8	62.0–67.6
No	1,422	35.2	32.4–38.0
Frequency of alcohol use
Daily	308	7.8	6.9–8.8
Weekly	821	20.7	18.9–22.5
Monthly	431	11.1	10.0–12.3
Less than monthly	972	25.2	23.6–26.8
Never	1,422	35.2	32.4–38.0
Binge drinking, past 30 days^e
Yes	632	16.1	14.4–17.8
No	3,301	83.9	82.2–85.6
Total	3,995	100

Abbreviation: CI, confidence interval.
Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Persons who drank ≥1 alcoholic beverage during the 12 months before interview. Alcoholic beverage was defined as a 12-ounce beer, 5-ounce glass of wine, or 1.5-ounce shot of liquor.
^e Persons who drank ≥5 alcoholic beverages in a single sitting (≥4 for women) during the 30 days before interview.

Table 13. Noninjection drug use during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, United States, 2021
	No.^a	%^b	95% CI^c
Use of any noninjection drugs^d
Yes	1,858	47.7	44.0–51.3
No	2,085	52.3	48.7–56.0
Noninjection drugs used^d
Marijuana^e
Yes	1,515	38.5	35.2–41.7
No	2,427	61.5	58.3–64.8
Amyl nitrite (poppers)
Yes	526	13.5	10.7–16.3
No	3,416	86.5	83.7–89.3
Methamphetamine (e.g., crystal meth, tina, crank, ice)
Yes	259	6.9	5.4–8.4
No	3,681	93.1	91.6–94.6
Cocaine that is smoked or snorted
Yes	248	6.4	5.3–7.4
No	3,694	93.6	92.6–94.7
Club drugs (e.g., Ecstasy or X, ketamine or Special K, GHB or Liquid Ecstasy)
Yes	176	4.7	3.7–5.6
No	3,765	95.3	94.4–96.3
Crack
Yes	137	3.6	2.8–4.4
No	3,805	96.4	95.6–97.2
Prescription opioids (e.g., oxycodone, hydrocodone, Vicodin, Percocet)^f
Yes	120	3.0	2.4–3.6
No	3,822	97.0	96.4–97.6
Prescription tranquilizers (e.g., Valium, Ativan, Xanax, downers, nerve pills)^f
Yes	87	2.1	1.5–2.7
No	3,855	97.9	97.3–98.5
Heroin or opium that is smoked or snorted
Yes	57	1.3	0.9–1.7
No	3,886	98.7	98.3–99.1
Total	3,995	100

Disclaimer: The use of trade names is for identification only and does not imply endorsement by the Department of Health and Human Services or the Centers for Disease Control and Prevention.
Abbreviations: CI, confidence interval; GHB, gamma hydroxybutyrate.
Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
Persons could report taking >1 noninjection drug.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Includes all drugs that were not injected (i.e., administered by any route other than injection), including legal drugs that were not used for medical purposes and vaping marijuana.
^e Includes vaping marijuana.
^f Not prescribed or prescribed but taken more than directed.

Table 14. Injection drug use during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, United States, 2021
	No.^a	%^b	95% CI^c
Use of any injection drugs
Yes	107	2.8	2.1–3.4
No	3,839	97.2	96.6–97.9
Injection drugs used
Methamphetamine (e.g., crystal meth, tina, crank, ice)
Yes	86	2.3	1.7–3.0
No	3,859	97.7	97.0–98.3
Heroin
Yes	23	0.6	0.3–0.8
No	3,923	99.4	99.2–99.7
Cocaine
Yes	15	0.5	0.2–0.7
No	3,931	99.5	99.3–99.8
Heroin and cocaine (speedball)
Yes	—	—	—
No	—	—	—
Prescription opioids (e.g., OxyContin, oxycodone, hydrocodone)
Yes	—	—	—
No	—	—	—
Total	3,995	100

Disclaimer: The use of trade names is for identification only and does not imply endorsement by the Department of Health and Human Services or the Centers for Disease Control and Prevention.
Abbreviation: CI, confidence interval.
Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30.
Persons could report taking >1 injection drug.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.

Table 15. Receipt of Papanicolaou testing and pregnancy since HIV diagnosis among cisgender women with diagnosed HIV—Medical Monitoring Project, United States, 2021
	No.^a	%^b	95% CI^c
Papanicolaou (Pap) test, past 3 years^d
Yes	798	83.0	79.6–86.4
No	160	17.0	13.6–20.4
Pregnant since HIV diagnosis
Yes	301	33.1	30.5–35.7
No	660	66.9	64.3–69.5
Total	983	100

Abbreviation: CI, confidence interval.
Note. Measures are self-reported. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Or since HIV diagnosis for women with a diagnosis within the past 3 years.

Table 16. Sexual behavior during the 12 months before interview among cisgender men and cisgender women with diagnosed HIV—Medical Monitoring Project, United States, 2021
	Cisgender Men			Cisgender Women
Behavior	No.^a	col %^b	95% CI^c	No.^a	col %^b	95% CI^c
Engaged in vaginal or anal sex
Yes	1,673	61.0	58.9–63.2	429	48.0	44.5–51.6
No	1,127	39.0	36.8–41.1	522	52.0	48.4–55.5
Engaged in vaginal sex
Yes	496	18.3	15.5–21.0	428	47.9	44.4–51.3
No	2,310	81.7	79.0–84.5	523	52.1	48.7–55.6
Engaged in anal sex with cisgender men
Yes	1,210	42.6	40.5–44.7	47	5.4	4.0–6.9
No	1,685	57.4	55.3–59.5	903	94.6	93.1–96.0
Engaged in anal sex with cisgender women
Yes	74	2.7	2.0–3.4	—	—	—
No	2,833	97.3	96.6–98.0	—	—	—
Number of vaginal or anal sex partners among sexually active persons:
MSM^d
Mean	7			—
Median	2			—
Range	1–359			—
MSW^e
Mean	1			—
Median	1			—
Range	1–30			—
WSM^f
Mean	—			1
Median	—			1
Range	—			1–20
Total	2,918	100		983	100

Abbreviations: CI, confidence interval; N/A, not applicable; MSM, cisgender men who had sex with cisgender men; MSW, cisgender men who had sex only with cisgender women; WSM, cisgender women who had sex with cisgender men.
Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Cisgender men who had anal sex with cisgender men in the 12 months before interview.
^e Cisgender men who had vaginal or anal sex only with cisgender women in the 12 months before interview.
^f Cisgender women who had vaginal or anal sex with cisgender men in the 12 months before interview.

Table 17. Sexual behavior during the 12 months before interview among transgender persons with diagnosed HIV—Medical Monitoring Project, United States, 2021
	Transgender^a			Transgender women^b			Transgender men^c
Behavior	No.^d	col %^e	95% CI^f	No.^d	col %^e	95% CI^f	No.^d	col %^e	95% CI^f
Engaged in vaginal or anal sex
Yes	58	71.6	63.2–80.0	54	74.4	66.3–82.4	—	—	—
No	28	28.4	20.0–36.8	24	25.6	17.6–33.7	—	—	—
Engaged in vaginal or anal sex with cisgender men
Yes	55	68.5	59.0–77.9	54	74.4	66.3–82.4	—	—	—
No	31	31.5	22.1–41.0	24	25.6	17.6–33.7	—	—	—
Engaged in vaginal or anal sex with cisgender women
Yes	—	—	—	—	—	—	—	—	—
No	—	—	—	—	—	—	—	—	—
Engaged in vaginal or anal sex with transgender partners
Yes	—	—	—	—	—	—	—	—	—
No	—	—	—	—	—	—	—	—	—
Reported any sex without using an HIV prevention strategy^g
Yes	—	—	—	—	—	—	—	—	—
No	—	—	—	—	—	—	—	—	—
Number of vaginal or anal sex partners^h
Mean	6			6			—	—	—
Median	2			2			—	—	—
Range	1–50			1–50			—	—	—
Total	91	100		82	100		9	100

Abbreviations: CI, confidence interval; PrEP, preexposure prophylaxis [footnotes only].
Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30.
^a Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose “transgender” in response to the question about self-identified gender.
^b Persons were classified as transgender women if sex at birth and gender reported by the person were different, or if the person reported that their sex assigned at birth was male, but identified as female or transgender.
^c Persons were classified as transgender men if sex at birth and gender reported by the person were different, or if the person reported that their sex assigned at birth was female, but identified as male or transgender.
^d Numbers are unweighted.
^e Percentages are weighted percentages.
^f CIs incorporate weighted percentages.
^g Vaginal or anal sex with at least 1 partner with an HIV-negative or unknown status while not having sustained viral suppression (defined as having all HIV viral loads being undetectable or <200 copies/mL, as documented in the medical record in the past 12 months before interview), a condom was not used, and the partner was not on PrEP. PrEP use was only measured among the 5 most recent sex partners.
^h Among persons who had vaginal or anal sex in the 12 months before interview.

Table 18. Sexual behavior during the 12 months before interview among cisgender men who had sex with cisgender men (MSM), cisgender men who had sex only with cisgender women (MSW), and cisgender women who had sex with cisgender men (WSM), with diagnosed HIV—Medical Monitoring Project, United States, 2021
	MSM			MSW			WSM
Behavior	No.^a	col %^b	95% CI^c	No.^a	col %^b	95% CI^c	No.^a	col %^b	95% CI^c
Engaged in any sex without using an HIV prevention strategy, among all persons^d
Yes	139	8.5	6.8–10.3	53	7.8	5.3–10.3	44	6.0	3.9–8.1
No	1,850	91.5	89.7–93.2	747	92.2	89.7–94.7	892	94.0	91.9–96.1
Engaged in any sex without using an HIV prevention strategy, among sexually active persons^d
Yes	139	13.6	10.9–16.3	53	13.7	9.4–17.9	44	12.4	8.3–16.4
No	1,079	86.4	83.7–89.1	393	86.3	82.1–90.6	384	87.6	83.6–91.7
Percentages of sexually active persons who used an HIV prevention strategy with at least 1 partner
Sex while having sustained viral suppression^e
Yes	843	63.0	59.3–66.8	297	61.0	56.0–66.1	295	63.7	57.2–70.2
No	378	37.0	33.2–40.7	150	39.0	33.9–44.0	134	36.3	29.8–42.8
Condom-protected sex^f
Yes	607	50.9	46.1–55.7	262	56.6	50.6–62.7	223	51.5	46.2–56.8
No	603	49.1	44.3–53.9	183	43.4	37.3–49.4	204	48.5	43.2–53.8
Condomless sex with a partner on PrEP^g
Yes	307	25.2	22.2–28.2	—	—	—	—	—	—
No	910	74.8	71.8–77.8	—	—	—	—	—	—
Sex with a partner with HIV^h
Yes	640	53.1	50.2–56.0	94	22.7	17.8–27.6	90	20.8	14.2–27.5
No	581	46.9	44.0–49.8	353	77.3	72.4–82.2	339	79.2	72.5–85.8
Total	2,022	100		811	100		946	100

Abbreviations: CI, confidence interval; MSM, cisgender men who had sex with cisgender men; MSW, cisgender men who had sex only with cisgender women; WSM, cisgender women who had sex with cisgender men; PrEP, preexposure prophylaxis.
Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
Persons who reported no anal, vaginal, or oral sex in the 12 months before interview were categorized according to self-reported sexual orientation. This table does not include information on cisgender women who had sex with cisgender women only, cisgender women who had sex with transgender persons only, or cisgender men who had sex with transgender persons only.
Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Vaginal or anal sex with at least 1 partner with an HIV-negative or unknown status while not having sustained viral suppression (defined as having all HIV viral loads being undetectable or <200 copies/mL, as documented in the medical record in the past 12 months before interview), a condom was not used, and the partner was not on PrEP. PrEP use was only measured among the 5 most recent sex partners.
^e Defined as having all HIV viral loads being undetectable or <200 copies/mL, as documented in the medical record in the past 12 months before interview.
^f Condoms were consistently used with at least 1 vaginal or anal sex partner.
^g At least 1 condomless-sex partner without HIV was on PrEP. PrEP use was only measured among the 5 most recent partners and was reported by the partner with HIV.
^h Sex with at least 1 partner with HIV.

Table 19. Met and unmet needs for HIV ancillary services during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, United States, 2021
	Among all persons with diagnosed HIV						Among persons with diagnosed HIV who had a need for the service
	Received services			Needed but did not receive services			Needed but did not receive services
	No.^a	col %^b	95% CI^c	No.^a	col %^b	95% CI^c	No.^a	col %^b	95% CI^c
HIV support services
HIV case management services
Yes	2,059	50.1	46.1–54.2	289	8.9	7.3–10.4	289	15.1	12.0–18.1
No	1,855	49.9	45.8–53.9	3,625	91.1	89.6–92.7	2,059	84.9	81.9–88.0
Medicine through ADAP
Yes	1,897	47.5	44.5–50.4	137	4.5	3.6–5.3	137	8.6	6.9–10.2
No	1,901	52.5	49.6–55.5	3,661	95.5	94.7–96.4	1,897	91.4	89.8–93.1
Professional help remembering to take HIV medicines on time or correctly (adherence support services)
Yes	1,213	29.9	25.8–33.9	31	0.8	0.5–1.0	31	2.5	1.5–3.5
No	2,716	70.1	66.1–74.2	3,898	99.2	99.0–99.5	1,213	97.5	96.5–98.5
Patient navigation services
Yes	505	11.2	9.4–13.1	198	5.7	4.8–6.6	198	33.6	27.4–39.9
No	3,418	88.8	86.9–90.6	3,725	94.3	93.4–95.2	505	66.4	60.1–72.6
HIV peer group support
Yes	375	7.9	7.0–8.8	306	8.8	7.5–10.1	306	52.7	47.5–58.0
No	3,554	92.1	91.2–93.0	3,623	91.2	89.9–92.5	375	47.3	42.0–52.5
Non-HIV medical services
Dental care
Yes	2,163	53.3	51.4–55.2	926	24.5	22.4–26.7	926	31.5	29.4–33.7
No	1,775	46.7	44.8–48.6	3,012	75.5	73.3–77.6	2,163	68.5	66.3–70.6
Mental health services
Yes	1,120	26.6	22.9–30.3	389	10.2	8.7–11.7	389	27.7	22.9–32.5
No	2,812	73.4	69.7–77.1	3,543	89.8	88.3–91.3	1,120	72.3	67.5–77.1
Drug or alcohol counseling or treatment
Yes	245	5.8	4.8–6.8	94	2.6	2.0–3.1	94	30.6	23.9–37.2
No	3,695	94.2	93.2–95.2	3,846	97.4	96.9–98.0	245	69.4	62.8–76.1
Domestic violence services
Yes	51	1.4	1.0–1.9	42	1.0	0.7–1.4	42	42.0	29.3–54.6
No	3,892	98.6	98.1–99.0	3,901	99.0	98.6–99.3	51	58.0	45.4–70.7
Subsistence services
SNAP or WIC
Yes	1,531	37.9	35.4–40.5	370	10.1	8.7–11.5	370	21.1	18.2–23.9
No	2,409	62.1	59.5–64.6	3,570	89.9	88.5–91.3	1,531	78.9	76.1–81.8
Meal or food services^d
Yes	773	19.0	17.0–21.1	275	7.4	6.4–8.4	275	27.9	24.3–31.5
No	3,169	81.0	78.9–83.0	3,667	92.6	91.6–93.6	773	72.1	68.5–75.7
Transportation assistance
Yes	790	18.7	17.5–20.0	318	8.3	7.4–9.3	318	30.8	27.8–33.9
No	3,156	81.3	80.0–82.5	3,628	91.7	90.7–92.6	790	69.2	66.1–72.2
Shelter or housing services
Yes	605	13.9	12.6–15.2	369	9.9	8.3–11.5	369	41.6	37.2–46.1
No	3,338	86.1	84.8–87.4	3,574	90.1	88.5–91.7	605	58.4	53.9–62.8
Total	3,995	100		3,995	100		3,995	100

Abbreviations: CI, confidence interval; ADAP, AIDS Drug Assistance Program; SNAP, Supplemental Nutrition Assistance Program; WIC, Special Supplemental Nutrition Program for Women, Infants, and Children.
Note. Persons could report receiving or needing more than 1 service. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Includes services such as soup kitchens, food pantries, food banks, church dinners, or food delivery services.

Table 20. Prevalence of physical violence by an intimate partner and forced sex among persons with diagnosed HIV—Medical Monitoring Project, United States, 2021
	No.^a	%^b	95% CI^c
Was ever slapped, punched, shoved, kicked, choked, or otherwise physically hurt by a romantic or sexual partner
Yes	1,062	28.6	26.7–30.5
No	2,827	71.4	69.5–73.3
Was slapped, punched, shoved, kicked, choked, or otherwise physically hurt by a romantic or sexual partner, past 12 months
Yes	161	4.9	3.8–6.0
No	3,725	95.1	94.0–96.2
Was ever threatened with harm or physically forced to have unwanted vaginal, anal, or oral sex
Yes	644	16.7	14.8–18.7
No	3,226	83.3	81.3–85.2
Was threatened with harm or physically forced to have unwanted vaginal, anal, or oral sex, past 12 months
Yes	44	1.4	0.8–1.9
No	3,825	98.6	98.1–99.2
Total	3,995	100

Abbreviation: CI, confidence interval.
Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.

Table 21. Prevention services received during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, United States, 2021
	No.^a	%^b	95% CI^c
Talked to a physician, nurse, or other health care worker about how to prevent HIV or other STDs
Yes	1,345	34.7	32.0–37.4
No	2,592	65.3	62.6–68.0
Talked to an outreach worker, counselor, or prevention program worker about how to prevent HIV or other STDs
Yes	672	16.6	13.6–19.6
No	3,259	83.4	80.4–86.4
Received free condoms, not counting those given by a friend, relative, or sex partner
Yes	1,118	28.6	25.7–31.5
No	2,828	71.4	68.5–74.3
Total	3,995	100

Abbreviation: CI, confidence interval.
Note. Persons could report receiving more than 1 prevention service.
Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.

Table 22a. National HIV/AIDS Strategy indicators: Self-rated health and unmet needs for mental health services during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, United States, 2021
	Good or better self-rated health^a			Unmet needs for mental health services among persons who needed mental health services^b
	No.^c	Row %^d	95% CI^e	No.^c	Row %^d	95% CI^e
Gender
Cisgender male	2,070	71.5	70.1–73.0	287	28.5	23.9–33.1
Cisgender female	569	60.7	55.6–65.7	91	24.9	16.6–33.3
Transgender^f	57	62.0	52.3–71.8	10	30.3*	13.4–47.1
Sexual orientation
Lesbian or gay	1,286	76.4	74.5–78.2	180	27.8	23.2–32.5
Heterosexual or straight	1,044	61.7	58.7–64.7	142	25.8	18.8–32.8
Bisexual	260	71.0	65.7–76.2	45	31.9	20.7–43.2
Other	76	59.0	49.8–68.2	—	—	—
Race/ethnicity
American Indian/Alaska Native	—	—	—	—	—	—
Asian	37	86.9	74.1–99.6	—	—	—
Black/African American	1,041	66.6	64.3–68.9	149	32.2	26.3–38.1
Hispanic/Latino^g	653	68.1	64.4–71.7	86	20.9	12.5–29.3
Native Hawaiian/other Pacific Islander	—	—	—	—	—	—
White	846	72.7	69.9–75.5	121	27.8	22.8–32.7
Multiple races	107	65.5	58.2–72.8	23	26.2	17.4–35.0
Age at time of interview (years)
18–29	215	80.8	75.7–85.9	42	38.2	25.6–50.7
30–39	482	76.3	72.2–80.4	91	31.8	25.8–37.8
40–49	532	73.1	69.4–76.8	71	27.3	19.8–34.7
≥50	1,468	63.2	61.1–65.2	185	24.4	18.6–30.1
National HIV/AIDS Strategy priority populations^h
All MSMⁱ	1,525	76.0	74.2–77.8	226	29.2	24.7–33.7
Black/African American MSMⁱ	419	77.4	74.0–80.7	67	34.8	28.5–41.2
Hispanic/Latino MSM^g,i	372	73.4	69.0–77.8	54	23.9	15.2–32.5
American Indian/Alaska Native MSMⁱ	—	—	—	—	—	—
Persons aged 18-24 years^j	50	87.5	82.0–93.0	—	—	—
Persons who inject drugs^k	61	57.7	46.5–68.8	20	28.9	14.9–42.9
Black/African American cisgender women	311	59.4	53.4–65.4	45	28.6	17.0–40.3
Transgender women^l	52	62.8	52.1–73.5	10	32.9*	14.9–51.0
Total	2,697	68.8	67.4–70.3	389	27.7	22.9–32.5

Abbreviations: CI, confidence interval; MSM, cisgender men who had sex with cisgender men.
Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30.
Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (*) and should be interpreted with caution.
^a “Good or better self-rated health” defined as rating one’s health as good, very good, or excellent (as opposed to poor or fair) at the time of interview.
^b “Unmet need for mental health services from a mental health professional” defined as needing, but not receiving, services from a mental health professional among those who indicated needing mental health services (i.e., receiving or needing but not receiving) during the past 12 months.
^c Numbers are unweighted.
^d Percentages are weighted percentages.
^e CIs incorporate weighted percentages.
^f Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose “transgender” in response to the question about self-identified gender.
^g Hispanics or Latinos can be of any race. Persons are classified in only 1 race/ethnicity category.
^h The National HIV/AIDS Strategy defines priority populations as populations that are disproportionately affected by HIV, and recommends that public health resources be delivered to priority populations for the greatest public health impact. For more information: https://www.hiv.gov/federal-response/national-hiv-aids-strategy/national-hiv-aids-strategy-2022-2025/
ⁱ Cisgender men who had anal sex with cisgender men in the 12 months before interview.
^j Priority population for youths includes persons aged 13-24 years; however, data from MMP are only available and presented for persons aged 18-24 years.
^k Defined as people who injected drugs in the past 12 months.
^l Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose “transgender” in response to the question about self-identified gender.

Table 22b. National HIV/AIDS Strategy indicators: Self-rated health and unmet needs for mental health services during the 12 months before interview among persons with diagnosed HIV, by cycle year—Medical Monitoring Project, United States, 2015-2021
	Good or better self-rated health^a			Unmet needs for mental health services among persons who needed mental health services^b
	No.^c	Row %^d	95% CI^e	No.^c	Row %^d	95% CI^e
Cycle year
2015	Data not collected			347	24.0	20.9–27.1
2016	Data not collected			350	23.8	20.7–26.9
2017	Data not collected			372	24.2	21.0–27.5
2018	2,825	71.5	69.4–73.6	317	19.8	17.1–22.5
2019	2,848	70.6	68.7–72.5	336	20.8	17.4–24.3
2020	2,621	71.5	70.0–73.1	275	21.0	18.2–23.8
2021	2,697	68.8	67.4–70.3	389	27.7	22.9–32.5

Abbreviations: CI, confidence interval.
Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
^a “Good or better self-rated health” defined as rating one’s health as good, very good, or excellent (as opposed to poor or fair) at the time of interview.
^b “Unmet need for mental health services from a mental health professional” defined as needing, but not receiving, services from a mental health professional among those who indicated needing mental health services (i.e., receiving or needing but not receiving) during the past 12 months.
^c Numbers are unweighted.
^d Percentages are weighted percentages.
^e CIs incorporate weighted percentages.

Table 23a. National HIV/AIDS Strategy indicators: Unstable housing or homelessness, unemployment, and hunger/food insecurity during the 12 months before interview among persons with diagnosed HIV, overall and by demographic characteristics—Medical Monitoring Project, United States, 2021
	Unstable housing or homelessness^a			Unemployment^b			Hunger/Food insecurity^c
	No.^d	Row %^e	95% CI^f	No.^d	Row %^e	95% CI^f	No.^d	Row %^e	95% CI^f
Gender
Cisgender male	471	16.6	14.7–18.4	420	14.7	13.3–16.2	423	14.9	13.1–16.7
Cisgender female	158	17.2	14.5–19.8	118	13.4	10.9–15.9	156	16.2	13.6–18.8
Transgender^g	21	27.1	17.1–37.1	20	24.7	15.3–34.2	28	36.8*	20.0–53.5
Sexual orientation
Lesbian or gay	231	14.5	12.3–16.6	247	15.2	12.9–17.5	219	13.9	12.0–15.9
Heterosexual or straight	287	17.0	15.2–18.8	228	13.8	11.6–16.0	276	16.4	14.5–18.2
Bisexual	88	23.7	18.0–29.5	55	14.3	10.6–17.9	67	15.8	12.1–19.6
Other	38	30.1	20.3–39.9	25	22.2	14.3–30.1	32	24.9	14.6–35.3
Race/ethnicity
American Indian/Alaska Native	—	—	—	—	—	—	—	—	—
Asian	—	—	—	—	—	—	—	—	—
Black/African American	297	19.7	17.4–22.0	240	16.2	13.8–18.5	239	15.3	13.5–17.1
Hispanic/Latino^h	172	16.1	13.3–18.8	141	14.7	11.3–18.2	191	19.3	16.4–22.2
Native Hawaiian/other Pacific Islander	—	—	—	—	—	—	—	—	—
White	121	12.1	9.5–14.8	135	11.7	9.6–13.8	116	11.7	9.6–13.7
Multiple races	49	28.2	18.8–37.6	36	19.3	14.1–24.6	52	26.7	19.0–34.5
Age at time of interview (years)
18–29	82	31.5	25.7–37.4	65	23.2	17.0–29.3	62	24.3	18.2–30.4
30–39	155	24.7	19.4–30.0	139	22.3	18.9–25.8	145	21.1	16.9–25.4
40–49	148	18.6	14.9–22.4	131	17.9	14.7–21.1	128	15.8	12.7–18.8
≥50	266	11.8	10.2–13.5	223	9.8	8.4–11.2	272	12.7	10.9–14.5
National HIV/AIDS Strategy priority populationsⁱ
All MSM^j	302	15.9	13.5–18.2	292	15.0	12.8–17.1	274	13.9	12.1–15.7
Black/African American MSM^j	104	19.4	14.1–24.7	96	18.1	14.1–22.0	89	15.4	12.3–18.5
Hispanic/Latino MSM^h,j	101	18.1	14.1–22.1	82	15.6	11.8–19.4	93	16.5	13.2–19.9
American Indian/Alaska Native MSM^j	—	—	—	—	—	—	—	—	—
Persons aged 18-24 years^k	17	26.1	14.5–37.7	—	—	—	19	30.5	18.0–43.1
Persons who inject drugs^l	44	45.7	34.8–56.6	40	38.8	25.9–51.6	39	36.9	27.2–46.5
Black/African American cisgender women	90	18.7	14.7–22.7	59	13.5	9.9–17.0	72	14.4	11.0–17.8
Transgender women^m	19	28.4	18.2–38.7	19	24.5	15.6–33.3	28	40.3*	23.8–56.8
Total	651	17.0	15.3–18.6	558	14.7	13.4–16.0	607	15.7	14.2–17.3

Abbreviations: CI, confidence interval; MSM, cisgender men who have sex with cisgender men.
Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30.
Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (*) and should be interpreted with caution.
^a “Unstable housing or homelessness” defined as experiencing unstable housing (i.e., moving in with others due to financial issues, moving 2 or more times, or being evicted at any time) or homelessness (living on the street, in a shelter, in a single-room–occupancy hotel, or in a car at any time) during the past 12 months.
^b Unemployed persons included those who reported being unemployed at the time of the interview, excluding persons who were unable to work.
^c “Hunger/food insecurity” defined as going without food due to lack of money during the past 12 months.
^d Numbers are unweighted.
^e Percentages are weighted percentages.
^f CIs incorporate weighted percentages.
^g Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose “transgender” in response to the question about self-identified gender.
^h Hispanics or Latinos can be of any race. Persons are classified in only 1 race/ethnicity category.
ⁱ The National HIV/AIDS Strategy defines priority populations as populations that are disproportionately affected by HIV, and recommends that public health resources be delivered to priority populations for the greatest public health impact. For more information: https://www.hiv.gov/federal-response/national-hiv-aids-strategy/national-hiv-aids-strategy-2022-2025/
^j Cisgender men who had anal sex with cisgender men in the 12 months before interview.
^k Priority population for youths includes persons aged 13-24 years; however, data from MMP are only available and presented for persons aged 18-24 years.
^l Defined as people who injected drugs in the past 12 months.
^m Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose “transgender” in response to the question about self-identified gender.

Table 23b. National HIV/AIDS Strategy indicators: Unstable housing or homelessness, unemployment, and hunger/food insecurity during the 12 months before interview among persons with diagnosed HIV, by cycle year—Medical Monitoring Project, United States, 2015-2021
	Unstable housing or homelessness^a			Unemployment^b			Hunger/Food insecurity^c
	No.^d	Row %^e	95% CI^f	No.^d	Row %^e	95% CI^f	No.^d	Row %^e	95% CI^f
Cycle year
2015	Data not collected			574	16.8	15.2–18.5	771	21.5	19.6–23.3
2016	Data not collected			640	15.7	14.2–17.3	865	21.2	19.6–22.9
2017	Data not collected			634	14.9	13.5–16.4	866	21.1	19.2–22.9
2018	870	21.0	19.5–22.6	550	13.9	12.6–15.1	802	19.5	18.2–20.8
2019	791	19.8	18.0–21.6	556	13.7	12.2–15.3	781	19.9	18.0–21.8
2020	630	17.2	15.2–19.2	644	18.1	16.5–19.7	592	16.4	15.2–17.6
2021	651	17.0	15.3–18.6	558	14.7	13.4–16.0	607	15.7	14.2–17.3

Abbreviations: CI, confidence interval.
Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding.
^a “Unstable housing or homelessness” defined as experiencing unstable housing (i.e., moving in with others due to financial issues, moving 2 or more times, or being evicted at any time) or homelessness (living on the street, in a shelter, in a single-room–occupancy hotel, or in a car at any time) during the past 12 months.
^b Unemployed persons included those who reported being unemployed at the time of the interview, excluding those unable to work.
^c “Hunger/food insecurity” defined as going without food due to lack of money during the past 12 months.
^d Numbers are unweighted.
^e Percentages are weighted percentages.
^f CIs incorporate weighted percentages.

Table 24a. National HIV/AIDS Strategy indicators: Median HIV stigma scores during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, United States, 2021
	No.^a	Median^b	95% CI^c
Gender
Cisgender male	2,726	27.9	26.4–29.4
Cisgender female	899	33.5	30.4–36.5
Transgender^d	85	34.2	28.6–39.9
Sexual orientation
Lesbian or gay	1,614	26.9	25.3–28.5
Heterosexual or straight	1,588	30.2	28.1–32.2
Bisexual	353	29.9	27.0–32.8
Other	120	32.6	25.1–40.1
Race/ethnicity
American Indian/Alaska Native	—	—	—
Asian	35	33.1	25.1–41.2
Black/African American	1,476	27.8	25.9–29.8
Hispanic/Latino^e	916	31.5	29.8–33.3
Native Hawaiian/other Pacific Islander	—	—	—
White	1,096	27.1	24.6–29.6
Multiple races	166	33.6	31.1–36.2
Age at time of interview (years)
18–29	251	32.5	29.1–36.0
30–39	601	31.9	29.0–34.8
40–49	702	31.2	28.4–33.9
≥50	2,158	27.0	25.2–28.8
National HIV/AIDS Strategy priority populations^f
All MSM^g	1,922	27.2	25.5–28.9
Black/African American MSM^g	529	25.4	23.5–27.3
Hispanic/Latino MSM^e,g	489	29.1	27.0–31.2
American Indian/Alaska Native MSM^g	—	—	—
Persons aged 18-24 years^h	54	42.1	33.4–50.9
Persons who inject drugsⁱ	105	35.0	26.8–43.3
Black/African American cisgender women	494	30.7	25.3–36.1
Transgender women^j	76	34.2	28.3–40.0
Total	3,712	28.8	27.6–30.1

Abbreviations: CI, confidence interval; MSM, cisgender men who have sex with cisgender men.
Note. “Median HIV stigma score” defined as the weighted median score on a 10-item scale ranging from 0 (no stigma) to 100 (high stigma) that measures 4 dimensions of HIV stigma: personalized stigma during the past 12 months, current disclosure concerns, current negative self-image, and current perceived public attitudes about people living with HIV, measured among persons aged ≥18 years with diagnosed HIV infection living in the United States and Puerto Rico. The HIV stigma scale used for this indicator is available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001277/ [Wright K, Naar-King S, Lam P, Templin T, Frey M. Stigma scale revised: reliability and validity of a brief measure of stigma for HIV+ youth. J Adolesc Health 2007;40(1):96–98].
Numbers might not add to total because of “don’t know” and skipped (missing) responses.
Excluded are estimates with a denominator sample size <30.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose “transgender” in response to the question about self-identified gender.
^e Hispanics or Latinos can be of any race. Persons are classified in only 1 race/ethnicity category.
^f The National HIV/AIDS Strategy defines priority populations as populations that are disproportionately affected by HIV, and recommends that public health resources be delivered to priority populations for the greatest public health impact. For more information: https://www.hiv.gov/federal-response/national-hiv-aids-strategy/national-hiv-aids-strategy-2022-2025/
^g Cisgender men who had anal sex with cisgender men in the 12 months before interview.
^h Priority population for youths includes persons aged 13-24 years; however, data from MMP are only available and presented for persons aged 18-24 years.
ⁱ Defined as people who injected drugs in the past 12 months.
^j Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose “transgender” in response to the question about self-identified gender.

Table 24a. National HIV/AIDS Strategy indicators: Median HIV stigma scores during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, United States, 2021
	No.^a	Median^b	95% CI^c
Cycle year
2018	3,824	31.2	30.3–32.1
2019	3,904	30.7	29.2–32.1
2020	3,518	28.4	27.7–29.2
2021	3,712	28.8	27.6–30.1

Abbreviations: CI, confidence interval.
Note. “Median HIV stigma score” defined as the weighted median score on a 10-item scale ranging from 0 (no stigma) to 100 (high stigma) that measures 4 dimensions of HIV stigma: personalized stigma during the past 12 months, current disclosure concerns, current negative self-image, and current perceived public attitudes about people living with HIV, measured among persons aged ≥18 years with diagnosed HIV infection living in the United States and Puerto Rico. The HIV stigma scale used for this indicator is available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001277/ [Wright K, Naar-King S, Lam P, Templin T, Frey M. Stigma scale revised: reliability and validity of a brief measure of stigma for HIV+ youth. J Adolesc Health 2007;40(1):96–98]. HIV stigma estimates are not available prior to 2018 cycle year.
Numbers might not add to total because of “don’t know” and skipped (missing) responses.
^a Numbers are unweighted.
^b Medians are weighted medians.
^c CIs incorporate weights.

Behavioral and Clinical Characteristics of Persons with Diagnosed HIV Infection—Medical Monitoring Project, United States 2021 Cycle (June 2021–May 2022): Tables